Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab (2017)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1056/NEJMoa1614062
- Subjects: COLESTEROL; FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO; ANTICORPOS MONOCLONAIS; DOENÇAS CARDIOVASCULARES
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: The New England Journal of Medicine
- ISSN: 0028-4793
- Volume/Número/Paginação/Ano: v. 376, n. 16, p. 1517-1526, 2017
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
RIDKER, Paul M. et al. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. The New England Journal of Medicine, v. 376, n. 16, p. 1517-1526, 2017Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614062. Acesso em: 19 abr. 2024. -
APA
Ridker, P. M., Tardif, J. -C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W., et al. (2017). Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. The New England Journal of Medicine, 376( 16), 1517-1526. doi:10.1056/NEJMoa1614062 -
NLM
Ridker PM, Tardif J-C, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab [Internet]. The New England Journal of Medicine. 2017 ; 376( 16): 1517-1526.[citado 2024 abr. 19 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614062 -
Vancouver
Ridker PM, Tardif J-C, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab [Internet]. The New England Journal of Medicine. 2017 ; 376( 16): 1517-1526.[citado 2024 abr. 19 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614062 - Foi com muita satisfação que recebemos o convite dos ...[Apresentação]
- Relation of Uric Acid to Serum Levels of High-Sensitivity C-Reactive Protein, Triglycerides, and High-Density Lipoprotein Cholesterol and to Hepatic Steatosis
- Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
- Elevated uric acid, the metabolic syndrome and cardiovascular disease [Editorial]: cause, consequence, or just a not so innocent bystander?
- Lipid-lowering treatment for homozygous familial hypercholesterolaemia [Carta]
- Statin Use Is Not Associated With Presence of and Severity of Nonalcoholic Fatty Liver Disease
- A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care?
- Relation of Hepatic Steatosis to Atherogenic Dyslipidemia
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
- Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome
Informações sobre o DOI: 10.1056/NEJMoa1614062 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
